Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
16 Dec 2021
Amplia Provides Updated Investor Presentation
15 Dec 2021
Update - Application for quotation of securities - ATX
14 Dec 2021
Update - Proposed issue of securities - ATX
10 Dec 2021
Entitlement Offer Completed
02 Dec 2021
Amplia Awarded $2.1M R&D Cash Flow Loan
24 Nov 2021
App 4D and Financial Report Half Year ended 30 Sep 2021
19 Nov 2021
Notice of Extraordinary General Meeting - 17 Dec 2021
18 Nov 2021
Summary Results - Successful Phase 1 Clinical Trial AMP945
17 Nov 2021
Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
16 Nov 2021
Becoming a Substantial Holder - Acorn Capital Limited
Previous
1
2
3
4
5
6
7
8
9
Next
